Helsinn Announces Attendance at the
CPhI 2017 Conference in Frankfurt
- Helsinn will be attending between 24-26 October at Booth Number 61B20, Hall 6.1 on the Integrated Pharma Gold corridor
- Helsinn will introduce its manufacturing facilities in Switzerland and its In and Out Licensing operations
Lugano, Switzerland, October 19, 2017 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that it will be attending the CPhI Worldwide 2017 Conference in Frankfurt in October.
The conference will be hosted between 24-26 October 2017 in Messe Frankfurt, Germany. Helsinn can be found at Booth Number 61B20, Hall 6.1 on the Integrated Pharma Gold corridor.
The Helsinn Group's Booth will showcase operations at Helsinn Advanced Synthesis, the Group's manufacturing facilities in Switzerland, which develops and manufactures Active Pharmaceutical Ingredients, Active Intermediates, High Potency Active Pharmaceutical Ingredients and most recently, anticancer compounds, under cGMP and fully compliant with global regulations established by the national health regulatory authorities. Its operations also include business development for third party contract manufacturing.
In addition, at its pharmaceutical corner, Helsinn Healthcare will provide an overview of its In and Out Licensing business related to finished products. The Out Licensing opportunities available will be presented and new In Licensing opportunities that can create meaningful synergies with the focus in cancer care, evaluated.
CPhI has hosted pharmaceutical industry events over 27 years which aim to drive growth and innovation throughout all functions of the global supply chain by bringing together niche providers and top buyers.
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.
For more information:
Helsinn Group Media Contact
Group Head of Communication
Tel: +41 (0) 91 985 21 21